Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Buys $18,000,008.00 in Stock

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Albert Cha purchased 1,058,824 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ KALV traded down $4.42 during midday trading on Friday, hitting $18.18. The stock had a trading volume of 200,222 shares, compared to its average volume of 46,875. The firm has a market capitalization of $379.83 million, a P/E ratio of -11.88 and a beta of 3.01. Kalvista Pharmaceuticals Inc has a 1-year low of $7.01 and a 1-year high of $23.97.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.14). The company had revenue of $3.72 million for the quarter, compared to analyst estimates of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. On average, equities analysts expect that Kalvista Pharmaceuticals Inc will post -1.78 earnings per share for the current fiscal year.

A number of analysts have issued reports on KALV shares. ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, September 12th. Cantor Fitzgerald initiated coverage on Kalvista Pharmaceuticals in a research note on Friday, September 21st. They issued an “overweight” rating and a $32.00 price objective on the stock. Finally, Roth Capital initiated coverage on Kalvista Pharmaceuticals in a research note on Tuesday, July 10th. They issued a “buy” rating and a $20.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $24.50.

Institutional investors have recently added to or reduced their stakes in the stock. Spark Investment Management LLC acquired a new position in Kalvista Pharmaceuticals during the 2nd quarter worth approximately $108,000. BlackRock Inc. lifted its position in Kalvista Pharmaceuticals by 203.8% during the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 10,871 shares in the last quarter. DRW Securities LLC lifted its position in Kalvista Pharmaceuticals by 37.3% during the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 5,600 shares in the last quarter. Stanley Laman Group Ltd. lifted its position in Kalvista Pharmaceuticals by 48.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after acquiring an additional 21,861 shares in the last quarter. Finally, Eventide Asset Management LLC lifted its position in Kalvista Pharmaceuticals by 26.9% during the 1st quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock worth $8,532,000 after acquiring an additional 191,000 shares in the last quarter. 36.79% of the stock is currently owned by hedge funds and other institutional investors.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: What are the most popular ETFs

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply